Jordi Remon: PECATI Trial – Lenvatinib Plus Pembrolizumab in Metastatic B3-Thymoma and Thymic Carcinoma
Jordi Remon, Thoracic Oncologist at CIOCC Barcelona, shared a post on X:
“PECATI Trial, lenvatinib plus pembrolizumab (20/200) a potential ttx for patients with metastatic pretreated B3-Thymoma or TC.
- mPFS 14.9mo
- ORR: 23.3%
- 1-y OS: 85.2%
- G3 irAEs: 14%
- Keep Dose intensity lenva first 8 weeks high PFS
Thanks to all authors!!”
Title: Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study
Authors: Elena Elimova, Jaffer Ajani, Howard Burris, Crystal S Denlinger, Yoon-Koo Kang, Jwa Hoon Kim, Keun-Wook Lee, Bruce Lin, Rutika Mehta, Do-Youn Oh, Sun Young Rha, Young Mi Seol, Lin Yang, Mark A Ozog, Phillip M Garfin, Geoffrey Ku
Read The Full Article at The Lancet Oncology.
Read Further on OncoDaily: New Paper Alert: Zanidatamab Plus Chemotherapy for HER2-Positive Gastro-Oesophageal Adenocarcinoma
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023